
|Videos|February 20, 2014
Sequencing Abiraterone and Enzalutamide in mCRPC
Author(s)Sumanta Kumar Pal, MD
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Advertisement
Clinical Pearls
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing abiraterone and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
- This study is a retrospective analysis aiming to characterize the activity of abiraterone following enzalutamide and vice versa
- Data sets like these are becoming increasingly important and speak to potential resistance that evolves when a patient receives one drug or the other for mCRPC
- This study, as well as others, have shown that receiving one drug may compromise the efficacy of the second
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















